TARS · NASDAQ
Tarsus Pharmaceuticals (TARS) Stock Price & Fundamentals
Tarsus Pharmaceuticals (TARS) closed at $743.98 on Oct 9, 2026, up 0.31% from the previous close of $741.66.
Share price, past year
1Y +15.01%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $743.98 |
| Sep 30, 2026 | $738.84 |
| Aug 31, 2026 | $764.17 |
| Jul 31, 2026 | $726.48 |
| Jun 30, 2026 | $680.85 |
| May 29, 2026 | $679.04 |
| Apr 30, 2026 | $673.56 |
| Mar 31, 2026 | $650.47 |
| Feb 27, 2026 | $616.58 |
| Jan 30, 2026 | $621.20 |
| Dec 31, 2025 | $636.22 |
| Nov 28, 2025 | $679.03 |
| Oct 31, 2025 | $649.61 |
Key statistics
- Market cap
- $32.19B
- P/E (TTM)
- —
- EPS (TTM)
- −$1.06
- Revenue (TTM)
- $606.33M
- Net income (TTM)
- −$46.48M
- Shares outstanding
- 43.3M
- Dividend yield
- —
- 52-week range
- $612.68 – $764.17
Tarsus Pharmaceuticals's market cap is $32.19B, based on a share price of $743.98 and 43.3M shares outstanding as of Jun 30, 2026.
Financials
Tarsus Pharmaceuticals reported revenue of $451.36M for fiscal 2025, up 146.71% from fiscal 2024.
Tarsus Pharmaceuticals reported a net loss of $66.42M in fiscal 2025.
Fiscal 2025 revenue was the highest in the 6 years shown.
Annual revenue
| Fiscal year | Revenue | Growth | Net income | Net margin | EPS (diluted) | Free cash flow |
|---|---|---|---|---|---|---|
| FY2025ended Dec 31, 2025 | $451.36M | +146.7% | −$66.42M | −14.7% | −$1.59 | −$22.31M |
| FY2024ended Dec 31, 2024 | $182.95M | +948.6% | −$115.55M | −63.2% | −$3.07 | −$84.59M |
| FY2023ended Dec 31, 2023 | $17.45M | −32.4% | −$135.89M | −778.9% | −$4.62 | −$119.00M |
| FY2022ended Dec 31, 2022 | $25.82M | −54.7% | −$62.09M | −240.5% | −$2.52 | −$49.54M |
| FY2021ended Dec 31, 2021 | $57.03M | — | −$13.83M | −24.3% | −$0.67 | $3.16M |
| FY2020ended Dec 31, 2020 | $0.00 | — | −$26.81M | — | −$4.32 | −$21.59M |
| Quarter | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| Q2 FY2026ended Jun 30, 2026 | $173.91M | −$18.55M | −$0.43 |
| Q1 FY2026ended Mar 31, 2026 | $162.05M | −$6.97M | −$0.16 |
| Q4 FY2025ended Dec 31, 2025 | $151.67M | −$8.37M | −$0.17 |
| Q3 FY2025ended Sep 30, 2025 | $118.70M | −$12.59M | −$0.30 |
| Q2 FY2025ended Jun 30, 2025 | $102.66M | −$20.34M | −$0.48 |
| Q1 FY2025ended Mar 31, 2025 | $78.34M | −$25.12M | −$0.64 |
| Q4 FY2024ended Dec 31, 2024 | $66.41M | −$23.11M | −$0.57 |
| Q3 FY2024ended Sep 30, 2024 | $48.12M | −$23.42M | −$0.61 |
Company profile
- Name
- Tarsus Pharmaceuticals, Inc.
- Ticker
- TARS
- Exchange
- NASDAQ
- Industry (SEC SIC)
- Biological Products, (No Diagnostic Substances)
- Headquarters
- 15440 Laguna Canyon Road, Irvine, CA 92618
- Incorporated in
- DE
- Fiscal year ends
- December
- SEC CIK
- 0001819790
Recent SEC filings
- Sep 10, 2026
- Aug 6, 2026
- Aug 6, 2026
- Aug 6, 2026
- Aug 6, 2026
- Jul 13, 2026
- Jul 8, 2026
- Jun 29, 2026
Frequently asked questions
What is Tarsus Pharmaceuticals's stock price?
Tarsus Pharmaceuticals (TARS) closed at $743.98 on Oct 9, 2026, up 0.31% from the previous close of $741.66.
What is Tarsus Pharmaceuticals's market cap?
Tarsus Pharmaceuticals's market cap is $32.19B, based on a share price of $743.98 and 43.3M shares outstanding as of Jun 30, 2026.
How much revenue does Tarsus Pharmaceuticals make?
Tarsus Pharmaceuticals reported revenue of $451.36M for fiscal 2025, up 146.71% from fiscal 2024.
Does Tarsus Pharmaceuticals pay a dividend?
Yes. Tarsus Pharmaceuticals declared $0.00 per share in dividends for fiscal 2025.
Sources and methodology
Fundamentals come from Tarsus Pharmaceuticals, Inc.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures